<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043819</url>
  </required_header>
  <id_info>
    <org_study_id>PSC-CP-001</org_study_id>
    <nct_id>NCT04043819</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis</brief_title>
  <official_title>Evaluation of Safety and Exploratory Efficacy of PSC-01, an Autologous Adipose-derived Stromal Vascular Fraction Cell Therapy Product for the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Personalized Stem Cells, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Personalized Stem Cells, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety of an intraarticular injection&#xD;
      of an investigational biologic product (IBP), PSC-01, the patient's own adipose-derived&#xD;
      stromal vascular fraction cells (SVF) extracted from a lipoaspirate sample, to treat the pain&#xD;
      of osteoarthritis in a single knee. The secondary objective is to get initial data on&#xD;
      efficacy of the PSC-01.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>3-4 months</time_frame>
    <description>The primary outcome measure of this study is to evaluate the safety of the investigational biological product, PSC-01.Safety will be assessed as the number of treatment-related adverse events as assessed by CTCAE v5.0. Adverse events will be assessed by physical examination, patient-reported health status, clinical pathology evaluations (cbc, chemistry, and urinalysis), and post-procedure clinical observations through the 84-day study period with post-treatment follow-up at 6 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in KOOS Measurement</measure>
    <time_frame>3-4 months</time_frame>
    <description>The secondary outcome measure of this study is to obtain initial data on the efficacy of PSC-01 on treating knee osteoarthritis. The efficacy primary outcome will be assessed using the KOOS knee survey with the five relevant subcategories of pain, symptoms, average daily living, sport/recreation, and quality of life measured at baseline, day 42 and day 84.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PSC-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will receive intraarticular injection of the investigational biological product, PSC-01.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSC-01</intervention_name>
    <description>PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.</description>
    <arm_group_label>PSC-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  If a woman of childbearing potential, the study participant must not be pregnant at&#xD;
             the time of consent and must take contraceptive measures to prevent a pregnancy while&#xD;
             actively participating in the study&#xD;
&#xD;
          -  The study participant may be of any gender or ethnic background.&#xD;
&#xD;
          -  Must experience knee pain at least weekly for at least 3 months.&#xD;
&#xD;
          -  Must have failed a minimum of 6 weeks of first line, conservative therapy&#xD;
&#xD;
          -  Demonstrated clinical and radiographic evidence of OA diagnosis&#xD;
&#xD;
          -  Grade 2, 3, or 4 Kellgren-Lawrence score in one knee.&#xD;
&#xD;
          -  Normal or within protocol approved limits of laboratory blood and urinalysis tests&#xD;
&#xD;
          -  Must be suitable for cellular therapy per the Investigator's opinion&#xD;
&#xD;
          -  Must be suitable for liposuction per the Investigator's opinion&#xD;
&#xD;
          -  Must possess the cognitive ability to understand the investigational nature of this&#xD;
             clinical trial and voluntarily provide consent for study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of OA in the contralateral knee with a Kellgren-Lawrence score greater than 2&#xD;
&#xD;
          -  If a woman of child-bearing potential, the study participant must not be pregnant or&#xD;
             attempt to become pregnant while actively taking part in the study.&#xD;
&#xD;
          -  Steroid injection in either knee within 60 days of providing informed consent&#xD;
&#xD;
          -  The subject must not be diagnosed with any of the following diseases at the time of&#xD;
             consent:&#xD;
&#xD;
               -  Osteonecrosis&#xD;
&#xD;
               -  Active autoimmune disease&#xD;
&#xD;
               -  Serious cardiac condition&#xD;
&#xD;
               -  Psychotic Diseases&#xD;
&#xD;
               -  Epilepsy&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
          -  Prescribed immunosuppressive therapy at the time of consent&#xD;
&#xD;
          -  Evidence of cancer at the time of consent&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  Regular smoker at the time of consent&#xD;
&#xD;
          -  Received experimental medication or participated in another clinical study within 60&#xD;
             days of providing informed consent&#xD;
&#xD;
          -  Concurrent diseases or circumstances that the Investigator judges to be a potential&#xD;
             risk to patient health or a confounding variable in the assessment of study endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Diego Orthobiologics Medical Group</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grossmont Orthopedic Medical Group</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Orthopedic Specialists Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthohealing Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cellular Orthopedics</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Regenerative Institute</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <zip>07927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RestorePDX</name>
      <address>
        <city>Beaverton</city>
        <state>Oregon</state>
        <zip>97008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cellular therapy</keyword>
  <keyword>stromal vascular fraction</keyword>
  <keyword>SVF</keyword>
  <keyword>KOOS</keyword>
  <keyword>autologous</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>MSC</keyword>
  <keyword>knee</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>adipose-derived mesenchymal stem cells</keyword>
  <keyword>Ad-MSC</keyword>
  <keyword>intraarticular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

